|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 3/22/17 Medizone International Inc 10-K 12/31/16 69:3.8M Federal Filings, LLC/FA |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 487K
2: EX-31.1 Certification -- §302 - SOA'02 HTML 25K
3: EX-31.2 Certification -- §302 - SOA'02 HTML 25K
4: EX-32.1 Certification -- §906 - SOA'02 HTML 21K
5: EX-32.2 Certification -- §906 - SOA'02 HTML 21K
12: R1 Document And Entity Information HTML 48K
13: R2 Consolidated Balance Sheets HTML 107K
14: R3 Consolidated Balance Sheets (Parentheticals) HTML 33K
15: R4 Consolidated Statements of Comprehensive Loss HTML 60K
16: R5 Consolidated Statements of Stockholders' Equity HTML 57K
(Deficit)
17: R6 Consolidated Statements of Stockholders' Equity HTML 28K
(Deficit) (Parentheticals)
18: R7 Consolidated Statements of Cash Flows HTML 93K
19: R8 Note 1 - Organization and Summary of Significant HTML 77K
Accounting Policies
20: R9 Note 2 - Property and Equipment HTML 33K
21: R10 Note 3 - Trademark and Patents HTML 32K
22: R11 Note 4 - Accounts Payable - Related Parties HTML 23K
23: R12 Note 5 - Accrued Expenses HTML 29K
24: R13 Note 6 - Accrued Expenses - Related Parties HTML 29K
25: R14 Note 7 - Notes Payable HTML 39K
26: R15 Note 8 - Notes Payable - Related Parties HTML 25K
27: R16 Note 9 - Warrant Liability HTML 33K
28: R17 Note 10 - Commitments and Contingencies HTML 31K
29: R18 Note 11 - Equity Transactions HTML 34K
30: R19 Note 12 - Common Stock Options HTML 54K
31: R20 Note 13 - Going Concern HTML 28K
32: R21 Note 14 - Subsequent Events HTML 25K
33: R22 Accounting Policies, by Policy (Policies) HTML 119K
34: R23 Note 1 - Organization and Summary of Significant HTML 53K
Accounting Policies (Tables)
35: R24 Note 2 - Property and Equipment (Tables) HTML 31K
36: R25 Note 3 - Trademark and Patents (Tables) HTML 31K
37: R26 Note 5 - Accrued Expenses (Tables) HTML 28K
38: R27 Note 6 - Accrued Expenses - Related Parties HTML 28K
(Tables)
39: R28 Note 7 - Notes Payable (Tables) HTML 37K
40: R29 Note 9 - Warrant Liability (Tables) HTML 31K
41: R30 Note 12 - Common Stock Options (Tables) HTML 43K
42: R31 Note 1 - Organization and Summary of Significant HTML 47K
Accounting Policies (Details)
43: R32 Note 1 - Organization and Summary of Significant HTML 29K
Accounting Policies (Details) - Schedule of
Earnings Per Share, Basic and Diluted
44: R33 Note 1 - Organization and Summary of Significant HTML 31K
Accounting Policies (Details) - Schedule of
Deferred Tax Assets and Liabilities
45: R34 Note 1 - Organization and Summary of Significant HTML 35K
Accounting Policies (Details) - Schedule of
Effective Income Tax Rate Reconciliation
46: R35 Note 1 - Organization and Summary of Significant HTML 24K
Accounting Policies (Details) - Schedule of
Effective Income Tax Rate Reconciliation
(Parentheticals)
47: R36 Note 2 - Property and Equipment (Details) HTML 23K
48: R37 Note 2 - Property and Equipment (Details) - HTML 34K
Schedule of Property, Plant and Equipment
49: R38 Note 3 - Trademark and Patents (Details) HTML 38K
50: R39 Note 3 - Trademark and Patents (Details) - HTML 32K
Schedule of Finite-Lived Intangible Assets
51: R40 Note 4 - Accounts Payable - Related Parties HTML 29K
(Details)
52: R41 NOTE 5 - ACCRUED EXPENSES (Details) - Schedule of HTML 30K
Accrued Liabilities
53: R42 Note 6 - Accrued Expenses - Related Parties HTML 25K
(Details)
54: R43 Note 6 - Accrued Expenses - Related Parties HTML 29K
(Details) - Schedule of Accrued Liabilities
55: R44 NOTE 7 - NOTES PAYABLE (Details) - Schedule of HTML 42K
Debt
56: R45 Note 7 - Notes Payable (Details) - Schedule of HTML 73K
Debt (Parentheticals)
57: R46 Note 8 - Notes Payable - Related Parties (Details) HTML 35K
58: R47 Note 9 - Warrant Liability (Details) HTML 32K
59: R48 Note 9 - Warrant Liability (Details) - Fair Value HTML 31K
Measurements, Recurring and Nonrecurring,
Valuation Techniques
60: R49 Note 10 - Commitments and Contingencies (Details) HTML 55K
61: R50 Note 11 - Equity Transactions (Details) HTML 67K
62: R51 Note 12 - Common Stock Options (Details) HTML 156K
63: R52 Note 12 - Common Stock Options (Details) - HTML 36K
Schedule of Fair Value Assumptions of Stock
Options
64: R53 Note 12 - Common Stock Options (Details) - HTML 40K
Schedule of Share-Based Compensation, Stock
Options, Activity
65: R54 Note 13 - Going Concern (Details) HTML 49K
66: R55 Note 14 - Subsequent Events (Details) HTML 40K
68: XML IDEA XML File -- Filing Summary XML 125K
67: EXCEL IDEA Workbook of Financial Reports XLSX 64K
6: EX-101.INS XBRL Instance -- mzei-20161231 XML 839K
8: EX-101.CAL XBRL Calculations -- mzei-20161231_cal XML 104K
9: EX-101.DEF XBRL Definitions -- mzei-20161231_def XML 637K
10: EX-101.LAB XBRL Labels -- mzei-20161231_lab XML 765K
11: EX-101.PRE XBRL Presentations -- mzei-20161231_pre XML 604K
7: EX-101.SCH XBRL Schema -- mzei-20161231 XSD 136K
69: ZIP XBRL Zipped Folder -- 0001185185-17-000634-xbrl Zip 104K
Exhibit 31.1
CERTIFICATION
I, David A. Esposito, certify that:
1. I have reviewed this Annual Report on Form 10-K of Medizone International, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a. Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated affiliate, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b. Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c. Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d. Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a. All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b. Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
| /s/ David A. Esposito | ||
| Name: | David A. Esposito | |
| Title: | Interim Chief Executive Officer (Principal Executive Officer) | |
| Date: | March 22, 2017 | |
| This ‘10-K’ Filing | Date | Other Filings | ||
|---|---|---|---|---|
 | ||||
| Filed on: | 3/22/17 | None on these Dates | ||
| For Period end: | 12/31/16 | |||
| List all Filings | ||||